University of Oxford scientists are trialling giving Ivermectin to over-50s with Covid symptoms to see if it can keep them out of hospital.
First COVID-19 outpatient study based on risk stratification and early antiviral treatment at the beginning of the disease.
Low-dose hydroxychloroquine combined with zinc and azithromycin was an effective therapeutic approach against COVID-19.
Significantly reduced hospitalisation rates in the treatment group.
Reduced mortality rates in the treatment group.
Hydroxychloroquine really works says Professor of Medicine Dr Peter McCullough, describing the treatment as “the most widely used therapeutic” to treat COVID-19 in the world.
“The chances that it doesn’t work are calculated to be one in 17 billion,” he told Sky News.
“There’s no controversy over whether or not hydroxychloroquine works. The controversy is on the public health approach to COVID-19.”
Mr McCullough said “the virus invades inside cells, so we have to use drugs that go inside the cell and work to reduce viral replication”.
“The drugs that work within the cell and actually reduce viral replication are hydroxychloroquine, Ivermectin, doxycycline and azithromycin”.
“Sadly, in the United States and I know in Australia this happens all the time, patients get no treatment whatsoever. They literally are told to stay at home until they are sick enough to go to the hospital”
“I think that honestly it’s atrocious.
“History will look back on that and think it was the worst way to handle a potentially fatal illness.”
The aim of this study was to describe the outcomes of patients with coronavirus disease 2019 (COVID-19) in the outpatient setting after early treatment with zinc, low-dose hydroxychloroquine and azithromycin (triple therapy) dependent on risk stratification. This was a retrospective case series study in the general practice setting. A total of 141 COVID-19 patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the year 2020 were included. The main outcome measures were risk-stratified treatment decision and rates of hospitalisation and all-cause death. A median of 4 days [interquartile range (IQR) 3-6 days; available for n = 66/141 patients] after the onset of symptoms, 141 patients (median age 58 years, IQR 40-67 years; 73.0% male) received a prescription for triple therapy for 5 days. Independent public reference data from 377 confirmed COVID-19 patients in the same community were used as untreated controls. Of 141 treated patients, 4 (2.8%) were hospitalised, which was significantly fewer (P < 0.001) compared with 58 (15.4%) of 377 untreated patients [odds ratio (OR) = 0.16, 95% confidence interval (CI) 0.06-0.5]. One patient (0.7%) in the treatment group died versus 13 patients (3.4%) in the untreated group (OR = 0.2, 95% CI 0.03-1.5; P = 0.12). No cardiac side effects were observed. Risk stratification-based treatment of COVID-19 outpatients as early as possible after symptom onset using triple therapy, including the combination of zinc with low-dose hydroxychloroquine, was associated with significantly fewer hospitalisations.
As professor of epidemiology at Yale School of Public Health, I have authored over 300 peer-reviewed publications and currently hold senior positions on the editorial boards of several leading journals. I am usually accustomed to advocating for positions within the mainstream of medicine, so have been flummoxed to find that, in the midst of a crisis, I am fighting for a treatment that the data fully support but which, for reasons having nothing to do with a correct understanding of the science, has been pushed to the sidelines. As a result, tens of thousands of patients with COVID-19 are dying unnecessarily. Fortunately, the situation can be reversed easily and quickly.
I am referring, of course, to the medication hydroxychloroquine. When this inexpensive oral medication is given very early in the course of illness, before the virus has had time to multiply beyond control, it has shown to be highly effective, especially when given in combination with the antibiotics azithromycin or doxycycline and the nutritional supplement zinc.
- As a result, tens of thousands of patients with COVID-19 are dying unnecessarily.
- An inexpensive and be highly effective treatment, especially when given early: Hydroxychloroquine in combination with the antibiotics azithromycin or doxycycline and zinc.
- The article, “Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis” was published in the American Journal of Epidemiology (AJE). It analyzed five studies, demonstrating clear benefits and safety of this treatment.
- Other studies include:
- an additional 400 high-risk patients treated by Dr. Vladimir Zelenko, with zero deaths;
- four studies totaling almost 500 high-risk patients treated in nursing homes and clinics across the U.S., with no deaths;
- a controlled trial of more than 700 high-risk patients in Brazil, with significantly reduced risk of hospitalization and two deaths among 334 patients treated with hydroxychloroquine;
- and another study of 398 matched patients in France, also with significantly reduced hospitalization risk.
- “Natural experiments:” northern Brazil state of Pará used hydroxychloroquine to reduce deaths.
- Hydroxychloroquine has shown major success when used early in high-risk people but, as one would expect for an antiviral, much less success when used late in the disease course.
- Delays in waiting before starting the medications can reduce their efficacy.
- FDA concerns about the drug did not announce is that these adverse events were generated from tens of millions of patient uses of hydroxychloroquine for long periods of time, often for the chronic treatment of lupus or rheumatoid arthritis.
- The harms are minuscule compared to the mortality occurring right now in inadequately treated high-risk COVID-19 patients.